Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT-NK Cell Therapy in Advanced Biliary Tract Cancer
NCT03358849Phase 1Completed
- Sponsor
- Yonsei University
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SMT-NK in biliary tract cancer (BTC), sponsored by Yonsei University. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
SMT-NK
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03358849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358849.